diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis immunisation
Vaccines · 2022–2022
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b conjugate vaccine Primary vaccination series against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b… | Mar 2022 | Recommended | input received Global Healthy Living Foundation Australia · GLHF Australia · Immunisation Foundation |
Who spoke
Global Healthy Living Foundation Australia · GLHF Australia · Immunisation Foundation
What the PBS pays
$5M in government benefit over 2024–25, across 38,485 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and haemophilus influenzae type b conjugate vaccine | $5M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.